podoplanin Inhibitors

Common podoplanin Inhibitors include, but are not limited to Cisplatin CAS 15663-27-1, Fluorouracil CAS 51-21-8, Taxol CAS 33069-62-4, Suberoylanilide Hydroxamic Acid CAS 149647-78-9 and Bortezomib CAS 179324-69-7.

Podoplanin, also known by its various aliases such as aggrus, T1-alpha, and gp38, is a type I transmembrane sialoglycoprotein. It has a diverse tissue distribution, being expressed in numerous cell types such as lymphatic endothelial cells, osteoblasts, and certain types of tumors. At the molecular level, podoplanin has multiple O-glycosylation sites in its extracellular domain, which play a vital role in its functionality. It's known to have a significant role in the formation of the lymphatic vascular system and the separation of the blood and lymphatic vasculatures. In addition, podoplanin's interaction with C-type lectin-like receptor 2 (CLEC-2) is fundamental in platelet aggregation, a crucial process in hemostasis.

Podoplanin inhibitors are a class of molecules that target and modulate the activity of podoplanin. Given the protein's role in various cellular processes, the inhibition of podoplanin can have a range of biochemical implications. These inhibitors might operate by preventing podoplanin's interaction with its binding partners, like CLEC-2, thereby impeding processes like platelet aggregation. Alternatively, they might inhibit the expression or the post-translational modifications of podoplanin, affecting its stability, localization, or functionality. The development and study of podoplanin inhibitors can provide invaluable insights into the protein's role in vascular development, hemostasis, and other physiological and biochemical pathways. Through the study of such inhibitors, the complex interplay of podoplanin in various cellular processes can be further elucidated, offering a deeper understanding of its significance in cellular and molecular biology.